| 1 |
CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies |
|
| | Roland Schwarting, Eric Behling, Ashleigh Allen, Vivian Arguello-Guerra, Tulin Budak-Alpdogan | | | Archives of Pathology & Laboratory Medicine. 2022; 146(4): 415 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone) |
|
| | Sundar V Cherukuri, Amit Sureen, Taylor Infante, Nevetha Rajendran, Osvaldo Padilla, Sumit Gaur | | | Cureus. 2021; | | | [Pubmed] [Google Scholar] [DOI] | |
|
